News | Ablation Systems | May 22, 2018

LuxCath Showcases OmniView Light-Guided Ablation Catheter at HRS 2018

Device sees into tissue to assess catheter-tissue contact and lesion progression during cardiac ablation in real time

LuxCath Showcases OmniView Light-Guided Ablation Catheter at HRS 2018

May 22, 2018 — LuxCath LLC showcased the next generation of its proprietary OmniView light-guided catheter ablation system at the 2018 Heart Rhythm Society (HRS) conference, May 9-12 in Boston. The OmniView light-guided ablation catheter is the only technology, according to the company, that can see into tissue during cardiac ablation and assess catheter-tissue contact and lesion progression in real time. This offers electrophysiologists a simple and more definitive end point for lesion quality, increasing the potential for complete and more effective cardiac ablation.

Cardiac ablation is a well-accepted treatment option for cardiac arrhythmias, performed more than 800,000 times every year globally. Currently, electrophysiologists rely on a range of indirect surrogate endpoints, such as temperature, power, duration and contact force, to assess lesion quality during the cardiac ablation procedure. However, these surrogate endpoints have been shown to be variable and potentially unreliable, and they do not directly assess tissue response in real time. Literature has shown single-procedure recurrence rates of 20-40 percent when ablating atrial fibrillation (AF), the most common form of arrhythmia.

The LuxCath OmniView light-guided catheter delivers and couples light into the tissue via an optical fiber embedded in the ablation catheter to assess tissue metabolic activity. The optical signal can be used to assess stability of catheter-tissue contact, tissue composition and lesion formation. The quality of these lesions is critical, as arrhythmia will recur if the lesions are not complete and uniform across the affected tissue. As lesions are formed, natural tissue fluorescence diminishes, indicating tissue destruction. This feedback mechanism allows the electrophysiologist to better assess the quality of the lesion formed. The next generation of the OmniView is orientation-independent, emitting light and seeing in all directions, allowing for optical signals at all angles of tissue contact.

“LuxCath has developed a promising and much needed technology with the OmniView light-guided ablation catheter, which has the potential to improve lesion quality and reduce procedure time while also making the procedure less operator dependent,” said Vivek Reddy, M.D., director of cardiac arrhythmia service for The Mount Sinai Hospital and the Mount Sinai Health System, and a LuxCath scientific advisory board member. “The light-guided technology is designed to signal to the operator when there is stable and consistent tissue contact, which is critical in achieving complete lesions. If the OmniView can deliver on the promise of its approach, light guidance has the potential to be the primary sensory modality in the catheter ablation treatment of AF.”

Separately, the company has announced the establishment of a scientific advisory board, with members including Reddy as well as:

  • David Haines, M.D., section head, Heart Rhythm, Beaumont Hospital, Royal Oak, Mich.;
  • Pierre Jais, M.D., co-director, L’institut de rythmologie et modélisation cardiaque, Bordeaux, France;
  • Andrea Natale, M.D., executive medical director, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center; and
  • Jeremy Ruskin, M.D., founder, director, Cardiac Arrhythmia Service, Massachusetts General Hospital.

For more information: www.luxcath.com

 

Related Content

FDA Approves Biosense Webster's Tag-Index Guided Ablation Software
Technology | Ablation Systems | October 09, 2018
Biosense Webster Inc. recently received approval from the U.S. Food and Drug Administration (FDA) for its Visitag...
Medtronic Cryoballoon Improves Quality of Life, Reduces Systems of Persistent Atrial Fibrillation
News | Ablation Systems | August 28, 2018
Medtronic plc announced new findings from the CRYO4PERSISTENT AF clinical trial demonstrating improved quality of life...
Thermedical Announces FDA IDE Approval for Clinical Study of Durablate Catheter
News | Ablation Systems | August 02, 2018
Thermedical announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device...
Boston Scientific to Acquire Cryterion Medical Inc.
News | Ablation Systems | July 13, 2018
Boston Scientific Corp. recently announced a definitive agreement to acquire Cryterion Medical Inc., a privately-held...
Treating AFib With Ablation Reduces Mortality and Stroke
News | Ablation Systems | July 05, 2018
Using catheter-based ablation instead of medications alone reduces the risks of death and stroke in patients with the...
The Kardium Globe combined mapping and ablation catheter. The device has a distal multi-electrode array consisting of 16 ribs with 122 gold-plated electrodes. Ablation can be done with up to 24 electrodes simultaneously.  #HRS2018

The Kardium Globe combined mapping and ablation catheter. The device has a distal multi-electrode array consisting of 16 ribs with 122 gold-plated electrodes. Ablation can be done with up to 24 electrodes simultaneously. 

News | Ablation Systems | May 21, 2018
May 21, 2018 — Complete pulmonary vein isolation (PVI) was achieved in more than 99 percent of patients in a first-in
CardioFocus Announces Successful Live Case Featuring HeartLight X3 System
News | Ablation Systems | May 17, 2018
Medical device manufacturer CardioFocus Inc. announced a successful live case featuring its HeartLight X3 System during...
Imricor MRI-Guided Cardiac Ablation Study Results to Be Presented at HRS 2018
News | Ablation Systems | May 10, 2018
Results from the clinical study to evaluate Imricor’s Vision-MR Ablation Catheter for the treatment of atrial flutter...
Biosense Webster Launches Carto Vizigo Bi-Directional Guidance Sheath
Technology | Ablation Systems | May 08, 2018
Biosense Webster Inc. announced its Carto Vizigo Bi-directional Guiding Sheath is now available in the United States....
Stereotaxis and Acutus Medical Announce Strategic Collaboration
News | Ablation Systems | May 04, 2018
Stereotaxis and Acutus Medical announced a strategic collaboration to integrate the Stereotaxis Niobe Magnetic...
Overlay Init